Antiretroviral Drug Poster Figure 2: Direct Injection vs. 10x Dilution of 10 ng/mL Protein Precipitated Human Plasma



Peaks	tR (min)	Precursor Ion	Product Ion	Product Ion
1. Lamivudine	0.55	230.0	112.0	95.1
2. Zidovudine	1.06	268.1	127.2	110.1
3. Nevirapine-d3 (IS)	1.46	270.3	229.1	-
4. Nevirapine	1.47	267.3	225.9	196.9
5. Efavirenz	1.96	316.1	243.8	168.1
6. Ritonavir	2.35	721.5	140.1	296.0

Column Raptor Biphenyl (cat.# 9309A52)
Dimensions: 50 mm x 2.1 mm ID
Particle Size: 2.7 µm
Pore Size: 90 Å
Guard Column: Raptor Biphenyl EXP guard column cartridge 5 mm, 2.1 mm ID, 2.7 µm (cat.# 9309A0252)
Temp.: 30 °C
Standard/Sample
Conc.: 10 ng/mL
Mobile Phase
A: Water + 0.01% acetic acid
B: Methanol + 0.01% acetic acid

Time (min)	Flow (mL/min)	%A	%B
0.00	0.8	90	10
1.00	0.8	40	60
2.50	0.8	0	100
2.51	0.8	90	10
4.50	0.8	90	10

Max Pressure: 400 bar
Detector MS/MS
Ion Mode: ESI+
Mode: Scheduled MRM
Instrument UHPLC
Sample Preparation A 100 µL aliquot of fortified human plasma was protein precipitated with 300 µL acetonitrile containing isotopically labelled internal standard in a 1.3 mL 96-well plate (cat.# 26495). The plate was sealed and centrifuged for 10 minutes at 4300 rpm and 8 °C. A portion of each sample extract was diluted 10x with mobile phase A. All samples (10x diluted and undiluted extracts) were injected.